Estrella Immunopharma (ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected Artemis T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, is now open for patient enrollment.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESLA:
- Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial
- Estrella Immunopharma Raises $3.35M in Private Placement
- Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement
- Estrella Immunopharma Advances STARLIGHT-1 Clinical Trial
- Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial